Nasdaq Stockholm AB: The observation status for Papilly AB (publ) (under name change to Bonzun AB (publ)) is removed (524/21)

On April 30, 2021, the shares in Papilly AB (publ) (the "Company") (under name
change to Bonzun AB (publ)) were given observation status after the Company had
entered into a letter of intent to acquire Bonzun Health Information AB,
resulting in a decision by Nasdaq Stockholm AB that the Company would have to
undergo an examination comparable to that conducted for an entirely new issuer
applying for admission to trading. 

On June 7, 2021, the Company issued a press release with information that it
had entered into an agreement to acquire Bonzun Health Information AB through
an issue in kind. The acquisition was conditional upon, inter alia, approval by
a general meeting of the Company's shareholders and Nasdaq Stockholm AB's
decision to admit the Company's shares to continued trading on Nasdaq First
North Growth Market. 

On August 31, 2021, the Company issued a press release with information that
Nasdaq Stockholm AB had approved the Company's shares for continued trading on
Nasdaq First North Growth Market. 

On September 30, 2021, the Company issued a press release with information that
an extraordinary general meeting of its shareholders had decided to approve the
acquisition of Bonzun Health Information AB through an issue in kind. 

With reference to the above, Nasdaq Stockholm AB decides to remove the
observation status for the shares in Papilly AB (publ) (PAPI, ISIN code
SE0005849205, order book ID 101907) with immediate effect. 

For further information concerning this exchange notice please contact Issuer
Surveillance, telephone [phone]. 

Nasdaq Stockholm AB